The Side Effects Of A Genzyme Corporation Deal; Already Benefiting From Firm's Production Woes, Rivals Foresee Wider Opening

Boston.com -- The potential buyout of Genzyme Corp., the state’s largest biotechnology company, could be a boon for a pair of foreign-based competitors that have been aggressively marketing rival treatments to challenge Genzyme’s lucrative enzyme replacement drugs.

Back to news